Summary

The global CAR T-cell therapy market is estimated to reach USD 29.0 Billion by 2029 from USD 5.5 billion in 2024, at a CAGR of 39.6% during the forecast period of 2024 to 2029. Market growth is driven by the rise in the global cancer prevalence. Technological advancements in CAR T-cell therapies and rising therapy development investment and funding is likely to propel the market growth. However, adverse effects associated with CAR T-cell therapy and high treatment costs are some of the major factors expected to restrain the market growth during the forecast period.

“Yescarta segment accounted for the highest share of 2023.”
Based on product, the CAR T-cell therapy market is broadly segmented into Abecma (idecabtagene vicleucel), Breyanzi (lisocabtagene maraleucel), Carvykti (ciltacabtagene autoleucel), Yescarta (axicabtagene ciloleucel), Tecartus (brexucabtagene autoleucel), Kymriah (tisagenlecleucel) and other products. The Yescarta segment held the largest market share in 2023. Market growth is attributed to high response rates and durable remissions of Yescarta in treating relapsed/refractory cancers leading to an increase in therapy adoption.

“The Hospitals End User segment held the dominant share in the CAR T-cell therapy market.”
Based on end users, the global CAR T-cell therapy market is segmented into hospitals, long term care facilities and specialty centers. In 2023, the hospitals segment emerged as the primary growth driver in the global CAR T-cell therapy market, with the highest CAGR during the forecast period. Hospitals are incorporating CAR T-cell therapies into their standard oncology treatment protocols. This trend is boosting demand for CAR T-cell treatments as more hospitals embrace these therapies. Furthermore, hospitals play a key role in facilitating clinical trials for CAR T-cell therapies. By actively participating in research initiatives and collaborations with pharmaceutical companies, hospitals contribute to expanding the evidence base and accelerating regulatory approvals, which in turn stimulates market growth.


“Asia Pacific region estimated to show fastest growth rate.”
The CAR T-cell therapy market is segmented into North America, Europe, Asia Pacific, Latin America and the Middle East & Africa. During the forecast period, Asia Pacific region is estimated to grow at the highest CAGR. The supportive regulatory frameworks, rich CAR T-cell therapy product pipeline and expedited approval processes facilitate quicker market entry for innovative therapies, driving growth in the Asia Pacific market. In addition, increasing collaborations between hospitals, universities, and industries in Chinaare expected to provide lucrative market growth. The rapid increase in clinical trials evaluating the safety and effectiveness of CAR T-cell therapy across diverse cancer types in China also signals significant advancements. These studies have demonstrated encouraging results in treating leukemia, lymphoma, and solid tumors, with specific patient cohorts showing substantial rates of complete remission and sustained responses. This trend highlights Asia Pacific’s progress in developing and validating CAR T-cell treatments, positioning the region as a key player in advancing therapeutic outcomes in oncology in CAR T-cell therapy.
The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Supply Side- 70%, and Demand Side - 30%
• By Designation (Supply Side): Managers - 45%, CXOs & Directors - 30%, Executives- 25%
• By Region: North America -40%, Europe -25%, Asia-Pacific -20%, Latin America -10%, MEA- 5%
List of Companies Profiled in the Report:
• Bristol-Myers Squibb Company (US)
• Gilead Sciences Inc. (US)
• Novartis AG (Switzerland)
• Johnson & Johnson (US)
• CARsgen Therapeutics Holdings Limited (China)
• IASO Biotherapeutics (China)
• JW (Cayman) Therapeutics Co. Ltd (China)
• ImmunoAct (India)
• CRISPR Therapeutics (Switzerland)
• Autolus Therapeutics (UK)
• Allogene Therapeutics (US)
• Cartesian Therapeutics Inc. (US)
• Guangzhou Bio-gene Technology Co. Ltd (China)
• Wugen (US).
Research Coverage:
This report provides a detailed picture of the CAR T-cell therapy market. It aims to estimate the size and future growth potential of the market across different segments, such as product, target, demographic, indications, end-users and region. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall CAR T-cell therapy market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.
The report provides insights on the following pointers:
• Analysis of key drivers (technological advancements in CAR T-cell therapies, growing cancer prevalence, and rising investment and funding for therapy development), restraints (high therapy costs and adverse effects), opportunities (expansion into solid tumors and collaborations and partnerships) and challenges (patient recruitment for trials and reimbursement issues) are influencing the growth of CAR T-cell therapy market.
• Product Development/Innovation: Detailed insights on newly launched products of the CAR T-cell therapy market.
• Market Development: Comprehensive information about lucrative markets – the report analyses the CAR T-cell therapy market across varied regions.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the CAR T-cell therapy market.
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players include Bristol-Myers Squibb Company (US), Gilead Sciences, Inc. (US), Novartis AG (Switzerland), Johnson & Johnson (US), JW (Cayman) Therapeutics Co. Ltd (China), ImmunoAct (India), among others in the CAR T-cell therapy market.

ページTOPに戻る

Table of Contents

1 INTRODUCTION 25
1.1 STUDY OBJECTIVES 25
1.2 MARKET DEFINITION 25
1.2.1 INCLUSIONS & EXCLUSIONS 26
1.3 MARKET SCOPE 26
1.3.1 MARKETS COVERED 26
1.3.2 REGIONS COVERED 27
1.3.3 YEARS CONSIDERED 27
1.3.4 CURRENCY CONSIDERED 28
1.4 STAKEHOLDERS 28
1.5 RECESSION IMPACT 28
2 RESEARCH METHODOLOGY 29
2.1 RESEARCH DATA 29
2.1.1 SECONDARY DATA 30
2.1.2 PRIMARY DATA 31
2.1.3 BREAKDOWN OF PRIMARIES 31
2.2 MARKET SIZE ESTIMATION 32
2.2.1 INSIGHTS FROM PRIMARY EXPERTS 35
2.2.2 SEGMENTAL MARKET SIZE ESTIMATION 36
2.3 GROWTH RATE ASSUMPTIONS 37
2.3.1 CAGR PROJECTIONS 37
2.3.2 IMPACT OF SUPPLY-SIDE AND DEMAND-SIDE FACTORS 38
2.4 VOLUME ESTIMATION 38
2.5 MARKET BREAKDOWN AND DATA TRIANGULATION 39
2.6 RESEARCH LIMITATIONS 40
2.7 STUDY ASSUMPTIONS 40
2.8 RISK ANALYSIS 41
2.9 RECESSION IMPACT ANALYSIS 41
3 EXECUTIVE SUMMARY 42
4 PREMIUM INSIGHTS 46
4.1 CAR T-CELL THERAPY MARKET OVERVIEW 46
4.2 NORTH AMERICA: CAR T-CELL THERAPY MARKET, BY PRODUCT AND COUNTRY (2023) 47
4.3 CAR T-CELL THERAPY MARKET SHARE, BY PRODUCT 48
4.4 CAR T-CELL THERAPY MARKET, BY END USER 48

5 MARKET OVERVIEW 49
5.1 INTRODUCTION 49
5.2 MARKET DYNAMICS 49
5.2.1 DRIVERS 50
5.2.1.1 Growing cancer prevalence 50
5.2.1.2 Technological advancements in CAR T-cell therapies 50
5.2.1.3 Rising investment and funding for therapy development 51
5.2.2 RESTRAINTS 52
5.2.2.1 High therapy costs 52
5.2.2.2 Adverse effects 53
5.2.3 OPPORTUNITIES 54
5.2.3.1 Expansion into solid tumors 54
5.2.3.2 Collaborations and partnerships 55
5.2.4 CHALLENGES 57
5.2.4.1 Patient recruitment for trials 57
5.2.4.2 Reimbursement issues 57
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 59
5.4 VALUE CHAIN ANALYSIS 60
5.5 ECOSYSTEM ANALYSIS 62
5.5.1 PRODUCTS 62
5.5.2 END USERS 63
5.5.3 REGULATORY BODIES 64
5.6 TECHNOLOGY ANALYSIS 65
5.6.1 KEY TECHNOLOGIES 65
5.6.1.1 CAR DESIGN AND OPTIMIZATION 65
5.6.1.2 VIRAL VECTOR TECHNOLOGY 65
5.6.1.3 CELL CULTURE AND EXPANSION TECHNIQUES 65
5.6.2 COMPLIMENTARY TECHNOLOGIES 66
5.6.2.1 GENE EDITING TECHNOLOGY (CRISPR-CAS9-BASED GENOME EDITING) 66
5.6.3 ADJACENT TECHNOLOGIES 67
5.6.3.1 MONITORING AND IMAGING TECHNOLOGIES 67
5.7 PATENT ANALYSIS 67
5.7.1 METHODOLOGY 68
5.7.2 NUMBER OF PATENTS FILED 68
5.7.3 INNOVATION AND PATENT APPLICATIONS 68
5.7.4 TOP APPLICANTS 69
5.8 PRICING ANALYSIS 71
5.8.1 AVERAGE SELLING PRICE, BY TYPE 72
5.8.2 AVERAGE SELLING PRICE, BY REGION 73
5.8.3 AVERAGE SELLING PRICE TREND, BY PRODUCT 74

5.9 KEY CONFERENCES & EVENTS, 2024–2O25 75
5.10 REGULATORY LANDSCAPE 76
5.10.1 REGULATORY SCENARIO 76
5.10.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 77
5.11 INVESTMENT & FUNDING SCENARIO 80
5.12 PORTER’S FIVE FORCES ANALYSIS 81
5.12.1 INTENSITY OF COMPETITIVE RIVALRY 82
5.12.2 BARGAINING POWER OF SUPPLIERS 82
5.12.3 BARGAINING POWER OF BUYERS 82
5.12.4 THREAT OF SUBSTITUTES 82
5.12.5 THREAT OF NEW ENTRANTS 82
5.13 KEY STAKEHOLDERS & BUYING CRITERIA 83
5.13.1 KEY BUYING CRITERIA 84
6 CAR T-CELL THERAPY MARKET, BY PRODUCT 86
6.1 INTRODUCTION 87
6.2 YESCARTA 88
6.2.1 INCREASING REACH TO DRIVE MARKET 88
6.3 KYMRIAH 90
6.3.1 APPROVAL FOR PEDIATRIC USE TO SUPPORT MARKET GROWTH 90
6.4 CARVYKTI 92
6.4.1 WIDESPREAD REACH TO ENSURE MARKET GROWTH 92
6.5 ABECMA 95
6.5.1 RISING RESEARCH FOR ALTERNATIVE INDICATIONS TO DRIVE MARKET 95
6.6 TECARTUS 97
6.6.1 GROWING FOCUS ON PATIENT-CENTRIC REIMBURSEMENT
TO PROPEL MARKET 97
6.7 BREYANZI 99
6.7.1 MULTIPLE INDICATIONS TO PROPEL MARKET GROWTH 99
6.8 OTHER PRODUCTS 102
7 CAR T-CELL THERAPY MARKET, BY TARGET 106
7.1 INTRODUCTION 107
7.2 CD19 107
7.2.1 RISING INDICATIONS IN PIPELINE TO DRIVE MARKET 107
7.3 BCMA 110
7.3.1 TECHNOLOGICAL ADVANCEMENTS IN CAR T-CELL THERAPY TO PROPEL MARKET GROWTH 110
7.4 OTHER TARGETS 113

8 CAR T-CELL THERAPY MARKET, BY INDICATION 117
8.1 INTRODUCTION 118
8.2 MULTIPLE MYELOMA 118
8.2.1 RISING INCIDENCE OF MULTIPLE MYELOMA TO DRIVE MARKET 118
8.3 B-CELL LYMPHOMA 121
8.3.1 RISING PREVALENCE TO PROPEL MARKET GROWTH 121
8.4 ACUTE LYMPHOBLASTIC LEUKEMIA 123
8.4.1 FOCUS ON AFFORDABLE CAR T-CELL THERAPIES TO DRIVE MARKET 123
8.5 OTHER INDICATIONS 126
9 CAR T-CELL THERAPY MARKET, BY DEMOGRAPHIC 130
9.1 INTRODUCTION 131
9.2 ADULTS 131
9.2.1 INCREASING NUMBER OF LYMPHOMAS TO DRIVE MARKET 131
9.3 PEDIATRICS 133
9.3.1 RISING PREVALENCE OF TARGET DISEASES TO PROPEL MARKET GROWTH 133
10 CAR T-CELL THERAPY MARKET, BY END USER 137
10.1 INTRODUCTION 138
10.2 HOSPITALS 138
10.2.1 GROWING PREVALENCE OF CANCER TO DRIVE MARKET 138
10.3 SPECIALTY CENTERS 140
10.3.1 GROWING RESEARCH COLLABORATIONS TO PROPEL MARKET 140
10.4 LONG-TERM CARE FACILITIES 143
10.4.1 GROWING CASES OF CHRONIC DISORDERS TO DRIVE MARKET 143
11 CAR T-CELL THERAPY MARKET, BY REGION 146
11.1 INTRODUCTION 147
11.2 NORTH AMERICA 147
11.2.1 NORTH AMERICA: RECESSION IMPACT 147
11.2.2 US 151
11.2.2.1 Rising R&D activities for CAR T-cell therapies to drive market 151
11.2.3 CANADA 154
11.2.3.1 Government initiatives for regenerative medicine research to drive market 154
11.3 EUROPE 156
11.3.1 EUROPE: RECESSION IMPACT 156
11.3.2 GERMANY 159
11.3.2.1 Rising focus on clinical research to drive market 159
11.3.3 UK 162
11.3.3.1 Rising technological advancements in automation to drive market 162
11.3.4 FRANCE 164
11.3.4.1 Growing focus on cell & gene therapy initiatives to boost demand 164
11.3.5 ITALY 167
11.3.5.1 Growth in biotech sector to drive market 167
11.3.6 SPAIN 169
11.3.6.1 Rising focus on cell therapies to support market growth 169
11.3.7 REST OF EUROPE 171
11.4 ASIA PACIFIC 174
11.4.1 ASIA PACIFIC: RECESSION IMPACT 174
11.4.2 CHINA 178
11.4.2.1 Rising number of CAR T-cell clinical trials to support market growth 178
11.4.3 JAPAN 181
11.4.3.1 Increasing product approvals to drive market 181
11.4.4 INDIA 183
11.4.4.1 Rising incidence of cancer and growing focus on product commercialization to boost demand 183
11.4.5 AUSTRALIA 185
11.4.5.1 Robust infrastructure for clinical trials and well-developed healthcare sector to drive market 185
11.4.6 SOUTH KOREA 188
11.4.6.1 Rising growth in biopharmaceutical industry to drive market 188
11.4.7 REST OF ASIA PACIFIC 190
11.5 LATIN AMERICA 192
11.5.1 LATIN AMERICA: RECESSION IMPACT 192
11.5.2 BRAZIL 195
11.5.2.1 High expenditure on healthcare to support market growth 195
11.5.3 REST OF LATIN AMERICA 198
11.6 MIDDLE EAST & AFRICA 200
11.6.1 MEA TO GROW AT SLOWER PACE DURING FORECAST PERIOD 200
11.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT 201
12 COMPETITIVE LANDSCAPE 204
12.1 OVERVIEW 204
12.2 KEY PLAYER STRATEGY/RIGHT TO WIN 204
12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN CAR T-CELL
THERAPY MARKET 205
12.3 REVENUE ANALYSIS 206
12.4 MARKET SHARE ANALYSIS 207
12.4.1 RANKING OF KEY MARKET PLAYERS 209
12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023 209
12.5.1 STARS 209
12.5.2 EMERGING LEADERS 210
12.5.3 PERVASIVE PLAYERS 210
12.5.4 PARTICIPANTS 210
12.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023 211
12.5.5.1 Company footprint 211
12.5.5.2 Product footprint 211
12.5.5.3 Target footprint 212
12.5.5.4 Indication footprint 212
12.5.5.5 Region footprint 213
12.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023 213
12.6.1 PROGRESSIVE COMPANIES 213
12.6.2 RESPONSIVE COMPANIES 213
12.6.3 DYNAMIC COMPANIES 214
12.6.4 STARTING BLOCKS 214
12.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023 215
12.7 VALUATION & FINANCIAL METRICS 216
12.7.1 FINANCIAL METRICS 216
12.7.2 COMPANY VALUATION 216
12.8 BRAND/PRODUCT COMPARISON 217
12.9 COMPETITIVE SCENARIO 218
12.9.1 PRODUCT LAUNCHES & APPROVALS 218
12.9.2 DEALS 219
12.9.3 EXPANSIONS 220
12.9.4 OTHER DEVELOPMENTS 220
13 COMPANY PROFILES 221
13.1 KEY PLAYERS 221
13.1.1 BRISTOL-MYERS SQUIBB COMPANY 221
13.1.1.1 Business overview 221
13.1.1.2 Products offered 223
13.1.1.3 Recent developments 223
13.1.1.3.1 Product approvals 223
13.1.1.3.2 Deals 225
13.1.1.4 MnM view 225
13.1.1.4.1 Key strengths 225
13.1.1.4.2 Strategic choices 225
13.1.1.4.3 Weaknesses & competitive threats 225
13.1.2 GILEAD SCIENCES, INC. 226
13.1.2.1 Business overview 226
13.1.2.2 Products offered 228
13.1.2.3 Recent developments 229
13.1.2.3.1 Product approvals 229
13.1.2.3.2 Deals 229
13.1.2.3.3 Other developments 230

13.1.2.4 MnM view 230
13.1.2.4.1 Key strengths 230
13.1.2.4.2 Strategic choices 231
13.1.2.4.3 Weaknesses & competitive threats 231
13.1.3 NOVARTIS AG 232
13.1.3.1 Business overview 232
13.1.3.2 Products offered 234
13.1.3.3 Recent developments 235
13.1.3.3.1 Product launches & approvals 235
13.1.3.3.2 Expansions 235
13.1.3.3.3 Other developments 236
13.1.3.4 MnM view 236
13.1.3.4.1 Key strengths 236
13.1.3.4.2 Strategic choices 236
13.1.3.4.3 Weaknesses and competitive threats 236
13.1.4 JOHNSON & JOHNSON 237
13.1.4.1 Business overview 237
13.1.4.2 Products offered 238
13.1.4.3 Recent developments 239
13.1.4.3.1 Product approvals 239
13.1.4.3.2 Deals 239
13.1.5 JW (CAYMAN) THERAPEUTICS CO. LTD. 240
13.1.5.1 Business overview 240
13.1.5.2 Products offered 241
13.1.5.3 Recent developments 241
13.1.5.3.1 Product approvals 241
13.1.5.3.2 Deals 242
13.1.6 IMMUNOADOPTIVE CELL THERAPY PRIVATE LIMITED (IMMUNOACT) 243
13.1.6.1 Business overview 243
13.1.6.2 Products offered 243
13.1.6.3 Recent developments 244
13.1.6.3.1 Deals 244
13.1.6.3.2 Other developments 245
13.1.7 CARSGEN THERAPEUTICS HOLDINGS LIMITED 246
13.1.7.1 Business overview 246
13.1.7.2 Products offered 247
13.1.7.3 Recent developments 247
13.1.7.3.1 Product approvals 247
13.1.7.3.2 Deals 248
13.1.7.3.3 Expansions 249

13.1.8 IASO BIOTHERAPEUTICS 250
13.1.8.1 Business overview 250
13.1.8.2 Products offered 250
13.1.8.3 Recent developments 251
13.1.8.3.1 Product approvals 251
13.1.8.3.2 Deals 251
13.2 OTHER PLAYERS 252
13.2.1 GUANGZHOU BIO-GENE TECHNOLOGY CO., LTD (HEDY GROUP CO., LTD.) 252
13.2.2 CARTESIAN THERAPEUTICS, INC. 253
13.2.3 AUTOLUS THERAPEUTICS 254
13.2.4 ALLOGENE THERAPEUTICS 255
13.2.5 CRISPR THERAPEUTICS 256
13.2.6 WUGEN 257
14 APPENDIX 258
14.1 DISCUSSION GUIDE 258
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 262
14.3 CUSTOMIZATION OPTIONS 264
14.4 RELATED REPORTS 264
14.5 AUTHOR DETAILS 265